Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Ascendis Pharma A/S	Evotec	TG Therapeutics	GW Pharmaceuticals	Arrowhead Pharmaceuticals
Symbol	NASDAQ:ASND	OTCMKTS:EVTCY	NASDAQ:TGTX	NASDAQ:GWPH	NASDAQ:ARWR
Price Information
Current Price	$138.18	$83.16	$41.48	$218.96	$66.47
52 Week Range	Buy	Hold	Buy	Hold	Buy
MarketRank™
Overall Score	1.5	0.5	1.8	1.3	1.5
Analysis Score	3.5	0.0	3.4	1.1	3.4
Community Score	2.6	2.5	3.3	3.0	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.0	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Hold	Buy
Consensus Price Target	$192.22	N/A	$63.33	$204.09	$85.31
% Upside from Price Target	39.11% upside	N/A	52.68% upside	-6.79% downside	28.34% upside
Trade Information
Market Cap	$7.43 billion	$6.84 billion	$5.83 billion	$6.86 billion	$6.90 billion
Beta	0.77	1.13	2.28	2.15	1.62
Average Volume	214,582	859	1,502,873	899,737	787,455
Sales & Book Value
Annual Revenue	$14.98 million	$500.07 million	$150,000.00	$311.33 million	$87.99 million
Price / Sales	495.81	13.68	38,876.72	22.05	78.41
Cashflow	N/A	$1.52 per share	N/A	$0.01 per share	N/A
Price / Cash	N/A	54.59	N/A	18,588.22	N/A
Book Value	$15.87 per share	$7.08 per share	$0.39 per share	$23.48 per share	$4.51 per share
Price / Book	8.71	11.75	106.36	9.33	14.74
Profitability
Net Income	$-244,180,000.00	$42.64 million	$-172,870,000.00	$-9,020,000.00	$-84,550,000.00
EPS	($5.25)	$0.56	($1.83)	($0.24)	($0.84)
Trailing P/E Ratio	N/A	462.03	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	608.22	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-4,042.79%	3.92%	-151,798.69%	-11.05%	-96.09%
Return on Equity (ROE)	-55.72%	3.96%	-223.96%	-7.46%	-17.37%
Return on Assets (ROA)	-49.42%	1.61%	-108.08%	-6.13%	-15.19%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.90%	0.09%	0.01%	N/A
Current Ratio	14.80%	2.19%	3.35%	5.13%	7.92%
Quick Ratio	14.80%	2.13%	3.35%	4.31%	7.92%
Ownership Information
Institutional Ownership Percentage	N/A	N/A	65.73%	81.00%	65.52%
Insider Ownership Percentage	40.00%	N/A	13.20%	3.10%	4.00%
Miscellaneous
Employees	482	3,572	272	1,161	232
Shares Outstanding	53.75 million	82.28 million	140.59 million	31.35 million	103.79 million
Next Earnings Date	5/18/2021 (Estimated)	5/13/2021 (Estimated)	5/10/2021 (Estimated)	8/5/2021 (Estimated)	8/4/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0.60 EPS americanbankingnews.com - May 4 at 11:46 PM
	Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results finance.yahoo.com - May 4 at 7:17 PM
	Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy? finance.yahoo.com - May 3 at 2:13 PM
	Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position? finance.yahoo.com - April 30 at 2:10 PM
	ARWR: Raising target price to $84.00 finance.yahoo.com - April 29 at 8:24 PM
	Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease finance.yahoo.com - April 28 at 6:33 PM
	Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease finance.yahoo.com - April 28 at 8:32 AM
	Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a Suitable Stock for New Investors Now? stocksregister.com - April 24 at 9:03 AM
	When would be the best time to Buy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock? stocksregister.com - April 18 at 3:55 AM
	Interesting ARWR Put And Call Options For December 17th nasdaq.com - April 16 at 3:38 PM
	Notable Two Hundred Day Moving Average Cross - ARWR nasdaq.com - April 12 at 1:32 PM
	Analysts Anticipate Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Will Post Quarterly Sales of $91.23 Million americanbankingnews.com - April 11 at 1:54 AM
	Arrowhead Pharmaceuticals is Now Oversold (ARWR) nasdaq.com - March 5 at 5:51 PM
	Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia finance.yahoo.com - March 1 at 9:39 AM
	Accredited Virtual Event Preview- Corning, Cookware Covid finance.yahoo.com - February 26 at 2:19 PM
	These Analysts Just Made A Substantial Downgrade To Their Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) EPS Forecasts nasdaq.com - February 12 at 7:15 AM
	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Year's Estimates finance.yahoo.com - February 12 at 7:15 AM
	ARWR: Multiple Data Readouts in 2021… finance.yahoo.com - February 9 at 6:39 PM
	Arrowhead Pharmaceuticals, Inc (ARWR) Q1 2021 Earnings Call Transcript finance.yahoo.com - February 5 at 10:30 PM
	First Week of September 17th Options Trading For Arrowhead Pharmaceuticals (ARWR) nasdaq.com - January 19 at 5:03 PM
	Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results finance.yahoo.com - January 19 at 5:03 PM
	ARWR Jan 2021 65.000 call uk.finance.yahoo.com - December 31 at 11:12 PM
	ARWR Jan 2021 25.000 put uk.finance.yahoo.com - December 31 at 11:12 PM
	ARWR Feb 2021 105.000 call uk.finance.yahoo.com - December 31 at 1:07 PM
	ARWR Jan 2023 30.000 put uk.finance.yahoo.com - December 31 at 12:28 AM

Date	Company	Brokerage	Action
3/30/2021	Ascendis Pharma A/S	Oppenheimer	Downgrade
3/18/2021	Ascendis Pharma A/S	Canaccord Genuity	Boost Price Target
3/17/2021	Ascendis Pharma A/S	Credit Suisse Group	Lower Price Target
3/11/2021	Ascendis Pharma A/S	Stifel Nicolaus	Initiated Coverage
12/17/2020	Ascendis Pharma A/S	Berenberg Bank	Initiated Coverage
11/13/2020	Ascendis Pharma A/S	Morgan Stanley	Boost Price Target
11/12/2020	Ascendis Pharma A/S	Wells Fargo & Company	Boost Price Target
11/12/2020	Ascendis Pharma A/S	SVB Leerink	Boost Price Target
9/30/2020	Ascendis Pharma A/S	Wedbush	Boost Price Target
9/14/2020	Ascendis Pharma A/S	JPMorgan Chase & Co.	Initiated Coverage
5/20/2020	Ascendis Pharma A/S	CSFB	Boost Price Target
4/22/2021	Evotec	Deutsche Bank Aktiengesellschaft	Reiterated Rating
3/5/2021	Evotec	Citigroup	Downgrade
1/28/2021	Evotec	Royal Bank of Canada	Downgrade
4/26/2021	TG Therapeutics	HC Wainwright	Boost Price Target
4/26/2021	TG Therapeutics	The Goldman Sachs Group	Initiated Coverage
2/5/2021	TG Therapeutics	B. Riley	Boost Price Target
10/28/2020	TG Therapeutics	Cantor Fitzgerald	Boost Price Target
6/5/2020	TG Therapeutics	Evercore ISI	Initiated Coverage
2/22/2021	GW Pharmaceuticals	Raymond James	Reiterated Rating
2/3/2021	GW Pharmaceuticals	Northland Securities	Downgrade
2/3/2021	GW Pharmaceuticals	Needham & Company LLC	Reiterated Rating
8/10/2020	GW Pharmaceuticals	Guggenheim	Lower Price Target
8/7/2020	GW Pharmaceuticals	Bank of America	Reiterated Rating
2/5/2021	Arrowhead Pharmaceuticals	Piper Sandler	Boost Price Target
2/5/2021	Arrowhead Pharmaceuticals	Chardan Capital	Boost Price Target
12/21/2020	Arrowhead Pharmaceuticals	Robert W. Baird	Downgrade
12/15/2020	Arrowhead Pharmaceuticals	UBS Group	Initiated Coverage
11/19/2020	Arrowhead Pharmaceuticals	Smith Barney Citigroup	Initiated Coverage
11/19/2020	Arrowhead Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources